<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04609566</url>
  </required_header>
  <id_info>
    <org_study_id>SGN35-033</org_study_id>
    <secondary_id>KEYNOTE B81</secondary_id>
    <nct_id>NCT04609566</nct_id>
  </id_info>
  <brief_title>Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors</brief_title>
  <official_title>A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies After Progression on Prior PD-1 Inhibitor Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat&#xD;
      different types of cancer. There will be several different types of cancer studied in the&#xD;
      trial. The cancer must have spread to other parts of the body (metastatic) and must have&#xD;
      gotten worse (progressed) after being treated with a PD-1 inhibitor treatment.&#xD;
&#xD;
      The study will also find out what side effects occur. A side effect is anything the treatment&#xD;
      does besides treat cancer.&#xD;
&#xD;
      This is a multi-cohort study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed objective response rate (ORR) based on investigator assessment using RECIST 1.1 criteria</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Confirmed ORR per RECIST 1.1 is defined as the proportion of participants whose best overall response is a confirmed complete response (CR) or partial response (PR) per RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) based on investigator assessment using RECIST 1.1 criteria</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>DOR per RECIST 1.1 is defined as the time from start of the first documentation of confirmed objective tumor response (CR or PR) per RECIST 1.1 to the first documentation of PD (per RECIST v1.1) or to death due to any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) based on investigator assessment using RECIST 1.1 criteria</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>PFS is defined as the time from start of study treatment to first documentation of objective tumor progression (PD per RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR per iRECIST by investigator assessment</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>ORR per RECIST 1.1 is defined as the proportion of participants whose best overall response is confirmed CR or PR based on iRECIST guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR per iRECIST by investigator assessment</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>DOR per iRECIST is defined as the time from first documentation of confirmed objective response (CR or PR) based on iRECIST guidelines by investigator assessment to the first documentation of confirmed objective tumor progression per iRECIST by investigator assessment, or to death due to any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Analyses of AEs will be summarized with descriptive statistics.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Melanoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>brentuximab vedotin + pembrolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brentuximab vedotin</intervention_name>
    <description>1.8 mg/kg given into the vein (IV; intravenously) every 3 weeks</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <other_name>ADCETRIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>200 mg given intravenously every 3 weeks</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <other_name>KEYTRUDA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Must have relapsed or refractory metastatic squamous or nonsquamous non-small cell&#xD;
             lung cancer (NSCLC) (without known targetable EGFR, ALK, ROS1, or BRAF mutations) or&#xD;
             metastatic cutaneous melanoma (including participants without targetable gene&#xD;
             mutations and BRAF-V600E/V600K participants who have failed targeted therapy)&#xD;
&#xD;
          -  Participants must be currently on PD-1 checkpoint inhibitor (CPI) therapy (e.g.&#xD;
             nivolumab or pembrolizumab) or had their last dose of PD-1 CPI within 90 days prior to&#xD;
             enrollment; PD-1 inhibitor therapy must be the last previous line of therapy.&#xD;
&#xD;
          -  Participants must have progressed on treatment with an anti-PD-1 monoclonal antibody&#xD;
             (mAb) administered either as monotherapy, or in combination with other checkpoint&#xD;
             inhibitors or other therapies. PD-1 treatment progression is defined by meeting all of&#xD;
             the following criteria.&#xD;
&#xD;
               -  Participants with refractory disease must have progressed without a prior&#xD;
                  objective response during or after prior PD-1 inhibitor therapy within 3 months&#xD;
                  or have stable disease (SD) for &lt;6 months OR&#xD;
&#xD;
               -  Participants with relapsed diseased must have progressed after having developed a&#xD;
                  prior objective response of CR/PR for at least 3 months or SD for at least 6&#xD;
                  months AND&#xD;
&#xD;
               -  Have received at least 2 doses of an approved anti-PD-1 mAb.&#xD;
&#xD;
                    -  Have demonstrated disease progression (PD) after PD-1 as defined by RECIST&#xD;
                       v1.1. Progressive disease has been documented within 90 days from the last&#xD;
                       dose of anti-PD-1 mAb.&#xD;
&#xD;
          -  Tumor tissue sample obtained within 3 months prior to enrollment is required, and no&#xD;
             systemic anticancer therapy given after the sample was obtained.&#xD;
&#xD;
          -  An Eastern Cooperative Oncology Group (ECOG) Performance Status score of equal or less&#xD;
             than 1&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Has known active CNS metastases and/or carcinomatous meningitis.&#xD;
&#xD;
          -  Prior immunosuppressive chemotherapy, therapeutic radiation, or any immunotherapy&#xD;
             within 4 weeks of first study drug dose.&#xD;
&#xD;
          -  History of another malignancy within 3 years before the first dose of study drug or&#xD;
             any evidence of residual disease from a previously diagnosed malignancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Knowles, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seagen Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HOPE</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Kimball</last_name>
      <phone>520-324-4778</phone>
    </contact>
    <investigator>
      <last_name>Richard K Rosenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>cCARE - Northern</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Paz</last_name>
      <phone>559-326-1222</phone>
    </contact>
    <investigator>
      <last_name>Subramanyeswara Arekapudi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Hager, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Angeles Clinic and Research Institute, The</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Mata</last_name>
      <phone>310-231-2115</phone>
    </contact>
    <investigator>
      <last_name>Inderjit Mehmi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Inderjit Mehmi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research and Excellence Inc (cCARE)</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Bunnell</last_name>
      <phone>760-747-8935 ex508</phone>
      <email>sbunnell@ccare.com</email>
    </contact>
    <investigator>
      <last_name>Edward F McClay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital / University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Dickens</last_name>
    </contact>
    <investigator>
      <last_name>Karl Lewis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Jotte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginny Keeling</last_name>
      <phone>312-695-1365</phone>
    </contact>
    <investigator>
      <last_name>Sunandana Chandra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yousef Zakharia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela M Adkisson</last_name>
    </contact>
    <investigator>
      <last_name>John Hamm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology P.A.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Anderson</last_name>
      <phone>612-884-6331</phone>
    </contact>
    <investigator>
      <last_name>Timothy G Larson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C.</name>
      <address>
        <city>Clifton Park</city>
        <state>New York</state>
        <zip>12065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Moran</last_name>
      <phone>518-489-2607</phone>
      <email>Jennifer.Moran@USONCOLOGY.COM</email>
    </contact>
    <investigator>
      <last_name>Stephen Wrzesinski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Clary</last_name>
      <phone>800-710-4674</phone>
    </contact>
    <investigator>
      <last_name>David Waterhouse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic Cancer Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Gadus</last_name>
      <phone>419-479-5605</phone>
      <email>tgadus@toledoclinic.com</email>
    </contact>
    <investigator>
      <last_name>Rex Mowat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute/Oncology Assc of Oregon</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roosevelt Anderson</last_name>
      <phone>541-741-3451</phone>
      <email>Roosevelt.anderson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Joseph A Fiorillo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Austin Central</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisca Fernandez</last_name>
      <phone>512-427-9400</phone>
      <email>Francisca.Fernandez@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Yorio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Lopez</last_name>
      <phone>214-370-1846</phone>
      <email>rita.lopez2@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Charles Cowey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth 12th Avenue</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nori Sullivan</last_name>
      <phone>817-413-1760</phone>
      <email>Nori.sullivan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Rachel L Theriault</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Van Bebber</last_name>
      <phone>571-472-4724</phone>
    </contact>
    <investigator>
      <last_name>Sekwon Jang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendi Gobhardt</last_name>
      <email>wendi.gobhardt@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Graham T Watson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amanda L. Gillespie-Twardy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance / University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jake Thomson</last_name>
    </contact>
    <investigator>
      <last_name>Sylvia M Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Seattle Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Brentuximab Vedotin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

